Lundbeck planning for four novel drugs in phase 3 in 2026
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
Newsletters and Deep Dive digital magazine
Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from
Clinical trials for drug development are becoming increasingly complex, with numerous variables that must be identified and defined from the start.
Bayer has entered into an alliance with Impli, tapping into the start-up's implantable hormone-monitoring platform, which has potential in fertility treatment and other indications.
A UK initiative to tackle the "historically low" numbers of people taking part in dementia clinical trials has been launched with £20 million ($26 million) in funding from the government.
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as
Editor's Picks
Newsletters and Deep Dive
digital magazine